AMENDMENTS TO THE CLAIMS

Claim 1. (Currently Amended) A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID(s)) absorbed into porous particles, wherein the porous particles comprise a member selected from the group consisting of: dibasic calcium phosphate, anhydrous; microcrystalline cellulose; pregelatinised starch; calcium silicate; magnesium aluminometasilicate; and mixtures thereof.

Claim 2. (Original) The solid drug delivery composition according to claim 1 wherein one or more NO- donating NSAID(s) in oily form is absorbed into porous particles.

Claim 3. (Withdrawn) The solid drug delivery composition according to claim 1 wherein one or more NO- donating NSAID(s) in melted form is absorbed into porous particles.

Claim 4. (Canceled)

Claim 5. (Currently Amended) The solid drug delivery composition according to claim 1 wherein the porous particles are spherical with a particle size between 50 and 500 [[um]] μm.

Claim 6. (Currently Amended) The solid drug delivery composition according to claim 5 wherein the particle size of the spherical porous particles is between 100 and 150 [[um]] μm.

Claim 7. (Previously Presented) The solid drug delivery composition according to claim 1 wherein the pore size of the porous particles is between 10 and 1000 Å.

Claim 8. (Original) The solid drug delivery composition according to claim 7 wherein the pore size of the porous particles is between 20 and 750 Å.

Claim 9. (Original) The solid drug delivery composition according to claim 8 wherein the pore size of the porous particles is between 50 and 500 Å.

Claim 10. (Withdrawn) The solid drug delivery composition according to claim 1 wherein one or more NO-donating NSAID(s) is absorbed together with one or more surfactant (s) into the porous particles.

Claim 11. (Withdrawn) The solid drug delivery composition according to claim 1 comprising a combinations of
a) porous particles comprising an NO-donating NSAID and one or more surfactant(s) and
b) porous particles comprising an NO-donating NSAID without surfactant.

Claim 12. (Withdrawn) The solid drug delivery composition according to claim 10 wherein the NO-donating NSAID(s) are the same.

Claim 13. (Withdrawn) The solid drug delivery composition according to claim 10 wherein the surfactant (s) is non-ionic.

Claim 14. (Withdrawn) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a block co-polymer.

Claim 15. (Withdrawn) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a poloxamer.

Claim 16. (Withdrawn) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a polyoxyethylene polyoxybutylene block copolymer.

Claim 17. (Withdrawn) The solid drug delivery composition according to claim 10 wherein the ratio NO-donating NSAID(s): surfactant(s) is within the range from 1:0.1 to

1:10(w/w).

Claim 18. (Withdrawn) The solid drug delivery composition according to claim I7 wherein the ratio NO-donating NSAID(s): surfactant(s) is within the range from 1:0.3 to 1:3(w/w).

Claim 19. (Previously Presented) The solid drug delivery composition according to claim 1 wherein the NO-donating NSAID is an NO-donating naproxen.

Claim 20. (Original) The solid drug delivery composition according to claim 19 wherein the NO-donating naproxen is 4-(nitrooxy)butyl-(S)-2- (9-methoxy-2-naphtyl)-propanoate.

Claim 21. (Withdrawn) The solid drug delivery composition according to claim 1 wherein the NO-donating NSAID is an NO-donating diclofenac.

Claim 22. (Withdrawn) The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4- (nitrooxy)-butyl ester.

Claim 23. (Withdrawn) The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2, 6-dichlorophenyl)amino] phenyl} acetate.

Claim 24. (Withdrawn) The solid drug delivery-composition according to claim 1 wherein the NO-donating NSAID is an NO-donating ketoprofen.

Claim 25. (Withdrawn) The solid drug delivery composition according to claim 24 wherein the NO-donating ketoprofen is 2-(3-benzoyl-phenyl)-propionic acid 3-nitrooxy-propyl ester or 2-(3-benzoyl-phenyl)-propionic acid 4-nitrooxymethyl-benzyl ester.

Claim 26. (Withdrawn) The solid drug delivery composition according to claim 1 wherein the porous particles comprising an NO-donating NSAID, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising a H+,K+-ATPase inhibitor.

Claim 27. (Withdrawn) The solid drug delivery composition according to claim 26 wherein the porous particles comprising an NO-donating naproxen, an NO-donating diclofenac, an NO-donating ketoprofen or an NO-donating ketorolac, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising omeprazole, esomeprazole, lansoprazole, pantoprazole or rabeprazole, leminoprazole or a pharmaceutical acceptable salt thereof.

Claim 28. (Withdrawn) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to claim 1 comprising mixing the NO-donating NSAID(s), optionally in oily or melted form, with porous particles.

Claim 29. (Withdrawn) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to claim 1 comprising:
a) dissolving the NO-donating NSAID(s) in one or more alcohol(s),
b) adding the porous particles during stirring,
c) evaporating the added alcohol(s),
d) recovering the porous particles comprising the NO-donating NSAID(s),
with a) and b) in optional order.

Claim 30. (Withdrawn) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to claim 1 comprising:
a) melting the NO-donating NSAID(s),
b) adding the porous particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising the NO-donating NSAID(s),

with a) and b) in optional order.

Claim 31. (Withdrawn) Process for producing porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to claim 1 comprising:
a) mixing the NO-donating NSAID(s) and the surfactant(s),
b) adding the porous particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising the NO-donating NSAID(s) and the surfactant(s),
with a) and b) in optional order.

Claim 32. (Withdrawn) Process for producing the porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to claim 1 comprising :
a) melting NO-donating NSAID(s) and the surfactant(s),
b) adding the porous particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising NO-donating NSAID(s) and the surfactant (s),
with a) and b) in optional order.

Claim 33. (Withdrawn) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to claim 1 comprising:
a) mixing the NO-donating NSAID(s) and the porous excipient,
b) adding water, stepwise, continuously, in one portion,
c) extruding the obtained mixture into particles,
d) spheronising the obtained particles,
e) drying the obtained mixture,
f) recovering the porous particles comprising the NO-donating NSAID(s).

Claim 34. (Withdrawn) The process according to claim 33 wherein the NO-donating NSAID(s) in step a) is pre-heated.

Claim 35. (Withdrawn) The process according to claim 28 wherein the NO-donating NSAID(s) are the same.

Claim 36. (Withdrawn) A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s)) absorbed into porous particles wherein the porous particles have been produced according to claim 28, are mixed with pharmaceutically acceptable excipients and compressed into a tablet.

Claim 37. (Withdrawn) A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound(s) (NO-donating NSAID(s)) absorbed into porous particles wherein the porous particles have been produced according to claim 28, are filled into a capsule.

Claim 38. (Withdrawn) The solid drug delivery composition according to claim 36 wherein the capsules or tablets are coated.

Claim 39. (Withdrawn) Use of the solid drug delivery composition according to claim 1 for the manufacture of a medicament for treating pain.

Claim 40. (Withdrawn) Use of the solid drug delivery composition according to claim 1 for the manufacture of a medicament for treating inflammation.

Claim 41. (Withdrawn) A method for the treatment of pain comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to claim 1.

Claim 42. (Withdrawn) A method for the treatment of inflammation comprising oral

administration to a patient suffering therefrom a solid compound delivery composition according to claim 1.